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taller risk to develop a cancer. The elderly patients, because 
of the presence of concomitant pathologies, they set to the 
clinician particular problems and limitations in the 
therapeutic planning. Several groups have reported the value 
of combination of conservative surgery and 
radiochemotherapy or radical radiotherapy alone in patients 
affected by bladder cancer. In this study we have 
retrospectively analyzed the prognostic factors influencing 
survival and relapse free-survival after radiotherapy following 
transurethral resection (TURB) for bladder cancer.  
 
Material and Methods: Between May 2013 and December 
2014, 33 patients with bladder cancer have been treated at 
the Operative Unity of Radiotherapy and Radiobiology, 
Hospital of Catanzaro. Of these, 19 patients were treated 
with radiotherapy alone (RT) and nine with platin based 
radio-chemotherapy (RCT) after TURB. Overall survival (OS) 
and Relapse-Free Survival (RFS) were analyzed with the 
Kaplan and Meyer methods. Comparisons were made using 
the log-rank test. In the analysis, we proposed the following 
prognostic factors as affecting the development of relapse 
after initial treatment: Univariate analysis was performed for 
age, grade, R-status after initial TURB, T-category relevant 
to the endpoints initial response, survival and bladder 
preservation. 
 
Results: Median age was 78 years (range 66-90 years), while 
the median follow-up is 15 months (range 5-42 months). All 
patients were treated with three-dimensional conformal 
therapy (3D-CRT). The total dose of radiotherapy ranged 
5040 cGy to 6000 cGy. Complete remissions were achieved at 
57% after RT and TURB. Toxicity was acceptable. Further 
significant prognostic factors were pT-category and R-status. 
For all patients survival was 31% after 2 years and 25% at 4 
years, while the relapse-free survival rates were 19% and 15% 
at 2 and 4 years, respectively. In the univariate analysis the 
only significant factor for survival and relapse-free survival 
and bladder preservation was the R-status after initial TURB 
 
Conclusion: In conclusion, treatment of bladder cancer by 
TURB and RT alone is an alternative to primary cystectomy, 
for the elderly patients. Initial TURB is recommended to be 
as radical as possible. 
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Purpose or Objective: to compare 2 multifraction 
radiotherapy (RT)schedules in the palliation of painful bone 
metastases in elderly patients, assessed at baseline with the 
Cumulative Illness Rating Scale for Geriatrics (CIRS-G). 
 
Material and Methods: 132 elderly patients were analyzed. 
Seventy-seven patients received a single 8Gy in single 
fraction and 55 received 20 Gy in 5 fractions. The choice of 
the treatment schedule was related to comorbidity, 
disability, target size and compliance. Pain intensity was 
measured with Numeral Rating Scale (NRS: 0 = no pain; 10 = 
high pain). Complete response was defined a pain reduction > 
3 of three points, partial response as a pain reduction ≥2 (2 ≤ 
pain reduction ≤ 3), no response was defined by pain score < 
2. Pain evaluation was recorded at baseline and at 1-4-8 
weeks after completing RT. 
 
Results: overall response: 90.3% in 8 Gy arm (49.8% complete 
and 40.5% partial), 94.6% in 20 Gy arm (44.6% complete and 
50%partial). No high grade toxicity were reported. The relief 
of pain was attained faster with single fraction (p-value ~ 
0.2). We observed maximum response of pain control after 8 
weeks and no significant differences were noted between 
two groups. The re-treatment rate was 17.6% vs 11.1% 
respectively. 
 
Conclusion: no significant differences between the two arms 
in terms of pain response, pain control and toxicity. Our 
experience showed that not influenced by age, but in the 
elderly, life expectancy, comorbidities evaluated with the 
CIRS-G, and compliance, are crucial in selecting of shorter 
treatment. 
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Purpose or Objective: To evaluate stereotactic body 
radiation therapy (SBRT) for oligometastatic lung tumors in 
patients 75 years old or older. 
 
Material and Methods: Between 2002 and 2015, 24 elderly 
patients with 34 lung metastases were treated using SBRT at 
our institution. SBRT procedure involved: Slow-scan 
computed tomography (CT) simulation with immobilization 
devices, contouring the target volume in 3 sets of CTs, 
superimposing the volumes in the planning system to 
represent the internal target volume and dose calculation 
using heterogeneity correction. Radiation delivery with 
multiple static planar or non-coplanar beams and arc therapy 
assured conformal dose distribution and steep fall-off of the 
radiation. The prescribed dose was 3 fractions of 15 Gy each 
(90%) given in 6-10 days or a single 30-Gy fraction (10%), with 
at least 95 % of the ITV covered by the 95% isodose line. 
Dosimetric constraints were set for surrounding organs at 
risk. Repeated cone-beam CT were used to verify daily 
positioning. Toxicity and radiologic response were assessed in 
follow-up, using standardized criteria (RTOG and RECIST) and 
analyzed retrospectively. Survival rates and toxicities were 
calculated by the Kaplan-Meier method. 
 
Results: Median patient age was 79 years (75-85). The origin 
of the metastases was: non-small cell lung cancer (53 %), 
colorectal adenocarcinoma (24 %), urotelial tumors (8.5 %), 
thyroid carcinoma (8.5 %), endometrial adenocarcinoma (3%) 
and parotid tumor (3%). All patients had good performance 
status at the moment of treatment (ECOG PS 0-1). Fifty-six 
percent of all patients also received systemic treatment 
before or after SBRT. Mean tumor volume was 10.7 cm3 (0.5-
106). The only acute toxicity reported was rib pain, grade 2, 
in 1 patient. No grade > 3 acute or any chronic toxicities 
were identified. The median follow-up was 11 months (1-60). 
The 6, 12 and 18 month overall survivals were 97, 88 and 85 
%. Local control in the irradiated volume is 97 %, the only 
failure occurring in a patient who also had distal progression 
from colon adenocarcinoma. 
 
Conclusion: SBRT is an excellent treatment option for lung 
oligometastasis in elderly patients. Our encouraging results 
are in line with those reported in recent literature for 
younger patients.  
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Purpose or Objective: Some recent data has questioned the 
impact of larynx preservation strategy on overall survival. 
The median age of patients in most major larynx preservation 
trials was 55-60 years with little representation of the older 
age group. The aim of this study is to review the tolerance 
and outcomes of larynx preservation treatment in the older 
population (≥ 65). 
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Material and Methods: Data was obtained from the St. Luke's 
Radiation Oncology Network patient registry. Patients with 
stage III & IV non-metastatic laryngeal cancer who were fit 
for radical intervention and offered larynx preservation 
treatment were identified between 2008-2014. Those who 
were aged ≥ 65 years at the time of treatment were included 
in this study. 
 
Results: A total of 68 patients were identified who met the 
selection criteria. The majority of patients were male (88%) 
and between 65-74 years, with a median age of 70. Of the 
patients identified 6% of patients were changed from radical 
to palliative intent and received a radiation dose of ≤40Gy. 
Currently, 45% of patients are still alive with 10% having 
required salvage surgery in the form of total laryngectomy 
post treatment for local recurrence. Of those studied, 60% of 
patients received radiotherapy only and 40% received 
combined chemoradiation. Patients who had combined 
modality treatment had significant toxicity from 
chemotherapy related to myelosuppression and febrile 
neutropaenia. Among those who received chemotherapy 51% 
did not complete the prescribed chemotherapy course 
secondary to toxicity. There were 17 patients (25%) who 
required enteral feeding via a gastrostomy tube and 2 
requiring NG feeding during their treatment course. 
 
Conclusion: Patients who are 65 years or greater seem to 
tolerate combined chemoradiation poorly. The appropriate 
selection of patients suitable for larynx preservation 
treatment in this age group is vital in achieving comparable 
survival and outcomes to the published major trials.  
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Purpose or Objective: To evaluate the use of a new 
algorithm for making decisions in elderly early breast cancer 
patients after tumorectomy plus hormone therapy. 
 
Material and Methods: This is a prospective preliminary 
study stating in June 2014. According to the recommendation 
of the “Innovation and Best Practices” of the “IDC-Salud 
health group”, a new algorithm to manage elderly (> 70 
years) patients with early breast cancer after conservative 
surgery was designed. This procedure considered the results 
of the CALGB 9343 randomized trial for counseling patients 
about the convenience or not to use radiotherapy. Inclusion 
criteria included patients older than 70 years, early breast 
cancer (T ≤ 2cm, clinical N0), treated by tumorectomy. In 
order to decide whether or not to indicate external 
radiotherapy, the new algorithm took into account the 
following parameter: life expectation estimated by a 
specialist in Geriatric Oncology using primarily patients’ age 
and the Charlson Comorbidity Index Score. Decision was 
against to indicate radiotherapy in women fulfilling the 
following conditions: life expectation ≤ 5 years. Those 
patients were managed according to both the Canadian 
nomogram (www.tuftsmedicalcenter.org/ibtr/) which 
calculates the 10-years local recurrence risk; and the MD 
Anderson nomogram 
(www3.mdanderson.org/app/medcalc/bc_nomogram5/index.
cfm?pagename=opcs), which calculates the risk of 
mastectomy at both 5 and 10 years in elderly patients. The 
criteria to decide whether or not indicate radiation therapy 
in these patients was based on the calculated reduction in 
the rate of either local recurrence or mastectomy as follows: 
≤ 5% radiotherapy was not indicated; reduction between 5- 
10% individualize case, reduction ≥ 10% radiotherapy should 
be always indicated. All patients signed a consent form to 
participate in the study and to assume the risks of local 
recurrence and/or further mastectomy. 
 
Results: Since June 2014,191 women with breast cancer were 
attended. 14 for them, (7.3%) were older than 70 years. From 
them seven fulfill the inclusion criteria (3.6%) and were 
eligible for the study. They all accepted to be included in the 
study. Data related to decision making are shown in Table 1 
and 2. 
After a detailed discussion explaining in depth that the 
benefits of the treatment was below +/- 5% and the potential 
risks and side effects, 37.5% (3/7) declined to be treated 
being surprisingly those who potentially could be more 
benefited from this therapy as they were at higher risk of 
recurrence. 
 
Conclusion: Patients fulfilling the criteria represent a low 
proportion of breast cancer patients. This preliminary study 
suggests that cultural and psychological aspects should be 
taken into account when counseling elderly patients with 
breast cancer in early stages. 
 
Electronic Poster: Clinical track: Health services research / 
health economics  
 
 
EP-1450  
Incremental radiotherapy treatment complexity: the effect 
on daily patient treatment times 
A. Munshi
1Fortis Memorial Research institute, Radiation Oncology, 
Haryana, India 
1, T. Ganesh1, B. Mohanti1 
 
Purpose or Objective: Modern day radiation oncologists have 
multiple options of treatment techniques including 3 D 
conformal radiotherapy (3 D CRT), Intensity modulated 
radiotherapy (IMRT) (Step shoot and dynamic) and volumetric 
modulated arc therapy (VMAT). This study assessed the effect 
of incremental treatment complexity on patient treatment 
times and the treatment times for first day and subsequent 
day treatments.  
 
Material and Methods: From Nov 2014 to Feb 2015, data of 
all the patients treated in our department with all techniques 
(3D CRT, IMRT, and VMAT) was analyzed using the Mosaiq 
system. Treatment time as computed by Mosaiq is the 
difference between the time at which the patient record is 
opened in Mosaiq Sequencer for treatment and the time at 
which the activity is captured after all treatment fields are 
completed. Treatment time on the first day and subsequent 
days for each technique was separately analyzed. Data was 
analyzed using SPSS software. 
 
Results: All timings were recorded in minutes. First day 
treatment sessions: For 18 first day sessions of 3 D CRT, the 
average treatment time was 30.37 (SD ±11.57). For 81 first 
day VMAT treatments the average time was 29.49 (SD ± 
35.27) while the corresponding time for 5 dynamic and 
step/shoot IMRT sessions was 13.81 (SD ±7.72). Subsequent 
daily treatments: For 240 sessions of daily treatments of 3D 
CRT, the average treatment time was 15.53(SD ±12.31). For 
2412 daily treatment VMAT sessions, the average treatment 
time was 15.82 (SD ±15.37). For combined dynamic (117 
sessions) and step/shoot IMRT (33 sessions), the average 
treatment time was 19.62 (SD ± 5.77). Overall daily 
treatment times were similar for VMAT as compared to 3 
DCRT (p> 0.05). The difference in treatment times for first 
day treatment versus subsequent first day treatment were 
statistically significant for 3D CRT as well as VMAT.(p<0.05) 
 
Conclusion: More complex radiotherapy techniques like VMAT 
require nearly same treatment times compared to 3 D 
conformal techniques on a daily basis. However, first day 
treatment times for all treatment techniques are significantly 
